Oakwood Labs
Oakwood Labs is a private Ohio-based CDMO/CMO that develops and manufactures long-acting injectable pharmaceuticals using its patented Chroniject™ polymer microsphere platform, serving global pharma and biotech clients across CNS, oncology, and other therapeutic areas.
- Company typePrivate
- Founded1997
- HeadquartersOakwood, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Oakwood Labs does
Oakwood Laboratories (operating as Oakwood Labs) is a private, Cleveland, Ohio-based contract development and manufacturing organization (CDMO/CMO) specializing in long-acting injectable (LAI) pharmaceuticals built on its proprietary Chroniject™ microsphere technology platform. Founded in 1997 as a spin-off from Ben Venue Laboratories by Edward C. Smith and Mark T. Smith, the company operates an R&D facility in Oakwood Village and an FDA-approved aseptic GMP manufacturing facility in Solon, Ohio (qualified in 2005, last inspected in 2024 with no major findings). Chroniject™ is a patented polymer-based system using biodegradable PLA and PLGA polymers to encapsulate small molecules, peptides, and proteins, with customizable release profiles ranging from one week to one year, applied across CNS, oncology, ophthalmology, cardiovascular, and endocrine therapeutic areas.
Oakwood generates revenue through three streams: (i) CDMO services (feasibility assessments, formulation development, scale-up, analytical method development) billed on a fixed-fee, project-managed basis; (ii) commercial contract manufacturing, currently producing 5 FDA-approved products with 3 additional registrations pending; and (iii) licensing and co-development partnerships where external partners fund Phase 1-3 development in exchange for rights to programs such as the long-acting ketamine program licensed to PharmaTher in November 2025. The company serves global pharmaceutical and biotechnology clients, with 100+ long-acting injectable projects completed and a workforce of 51-100 employees under CEO Jeffrey Fehn, and reports no institutional capital raise, maintaining founder-controlled ownership.
Oakwood Labs firmographics
Firmographics- Name
- Oakwood Labs
- Legal name
- Oakwood Laboratories
- Website
- https://oakwoodlabs.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Oakwood Labs is a private Ohio-based CDMO/CMO that develops and manufactures long-acting injectable pharmaceuticals using its patented Chroniject™ polymer microsphere platform, serving global pharma and biotech clients across CNS, oncology, and other therapeutic areas.
- Ownership category
- akta.pro rank
Oakwood Labs industry classification
Industry- Product category
- Contract Pharmaceutical Manufacturing (CDMO/CMO)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Oakwood Labs is headquartered
LocationHeadquarters
- HQ city
- Oakwood
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Oakwood Labs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services: Contract Development and Manufacturing Organization services including feasibility assessments, formulation development, analytical method development, scale-up, and GMP manufacturing for long-acting injectable products. Work is performed on a fixed-fee basis with dedicated project teams.
- Contract Manufacturing (CMO): Contract manufacturing services for sterile injectable products including aqueous, solvent-based, and suspension-filled vials, as well as lyophilized products. Currently manufactures five commercial products for external partners with three additional registrations pending approval.
- Licensing and Co-development Partnerships: Strategic partnerships for co-development of internal pipeline programs. External partners fund ongoing development activities, Phase 1-3 clinical trials, and registration/commercialization efforts. Example: licensing agreement with PharmaTher for long-acting ketamine program.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Oakwood Labs product offering
Product offeringCore offering
Oakwood Labs is a contract development and manufacturing organization (CDMO/CMO) specializing in sustained-release injectable pharmaceuticals based on its patented Chroniject™ polymer microsphere technology. The company provides end-to-end services including feasibility assessments, formulation development, analytical method development, scale-up, and FDA-approved aseptic GMP manufacturing of long-acting injectables for clinical and commercial supply. Oakwood currently manufactures five FDA-approved commercial products for external partners, with three additional registrations pending approval.
Product overview
Oakwood Labs is a specialty pharmaceutical company offering a single integrated platform for sustained release injectable drug development and manufacturing. The core technology is Chroniject™, a patented polymer-based microsphere system that enables controlled drug delivery over durations from one week to one year. As a CDMO/CMO, Oakwood provides end-to-end services including feasibility assessments, formulation development, scale-up, analytical method development, GMP aseptic manufacturing for clinical materials, and commercial contract manufacturing—all leveraging the Chroniject™ technology platform for clients ranging from early-stage developers to global pharmaceutical firms.
Differentiator
Problem solved
Functional benefit
Brands
- Chroniject: Proprietary polymer-based microsphere technology platform for sustained release drug delivery, enabling precise control over drug release profiles ranging from weeks to years.
Products and services
- Chroniject™ Microsphere Technology Platform Proprietary polymer-based microsphere technology platform (using biodegradable PLA and PLGA polymers) for sustained release injectable drug delivery, enabling precise control over particle size distribution and customizable drug release profiles ranging from one week to one year. Compatible with small molecules, peptides, and proteins.
- Feasibility Assessment Services Early-stage formulation development service utilizing small batch sizes to enable rapid testing of trial batches and determine achievable target product profiles within 3-4 months. For pharmaceutical and biotech companies seeking long-acting injectable development.
- Formulation Optimization and Scale-Up Quality-driven scale-up service maintaining critical product attributes (particle size distribution, in vitro release profile) from 5-gram batches to multi-kilogram commercial-scale production using Quality by Design (QbD) and Design of Experiments (DoE). Demonstrated at 1, 2, and 8 kg batch sizes with lot-to-lot reproducibility.
- Analytical Method Development Comprehensive analytical testing services including method development, optimization, qualification, transfer, and full validation in accordance with globally harmonized regulatory guidelines. In-house capabilities include HPLC, UHPLC, GC, GPC, in vitro dissolution, laser diffraction particle sizing, DSC, UV/Vis, and Karl Fischer.
- GMP Aseptic Manufacturing (Clinical & Commercial) FDA-approved aseptic GMP manufacturing for clinical trial materials (Phase I, II, III) and commercial sterile injectable products. Capabilities include aqueous, solvent-based, and suspension formulations, lyophilized products, and microsphere presentations, with ISO 5/7/8 classified cleanroom areas.
- Commercial Contract Manufacturing (CMO) Services Commercial-scale contract manufacturing for sterile injectable products, including aqueous, solvent, suspensions, microspheres, and lyophilized presentations for human and veterinary use. Currently manufactures five FDA-approved commercial products for external partners.
Quantifiable outcome
- 100+ long-acting injectable projects completed
- +3 more outcomes
Companies that use Oakwood Labs
Customer profileSegments2 records
Ideal customer profiles2 records
Oakwood Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Oakwood Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PharmaTher Holdings Ltd.corePharmaTher secured exclusive rights to evaluate and license Oakwood's long-acting ketamine program aimed at treating neuropsychiatric disorders. The program focuses on developing a differentiated delivery method targeting indications such as treatment-resistant depression and Parkinson's disease-related dyskinesia. PharmaTher plans to advance clinical development within three months.
Scale indicators7 records
Recent moves5 records
Expansion highlights5 records
Oakwood Labs competitors and assessment
Company assessmentBroad incumbents
- Recipharm: Recipharm is a global CDMO with substantial sterile injectable manufacturing capability, including aseptic fill-finish and lyophilization for clinical and commercial supply. Its parenteral CDMO services overlap with Oakwood's contract manufacturing offering for pharmaceutical clients.
- Aenova: Aenova is a European-headquartered CDMO with significant sterile injectable manufacturing capacity, serving large pharmaceutical clients across solid, semi-solid and parenteral dosage forms. Its aseptic injectable capabilities overlap with Oakwood's contract manufacturing service line for small-molecule injectables.
- Vetter Pharma: Vetter is one of the largest global aseptic fill-finish CDMOs serving injectable products, including complex long-acting injectables for large pharmaceutical clients. While broader than Oakwood, its aseptic manufacturing and clinical-to-commercial injectable capabilities put it in direct competition for LAI development and manufacturing projects.
- Baxter BioPharma Solutions: Baxter BioPharma Solutions is a major contract manufacturer of sterile injectable pharmaceuticals, including lyophilized and liquid vials, pre-filled syringes and biologics. It competes with Oakwood for sterile injectable contract manufacturing and clinical-to-commercial aseptic fill-finish programs.
- Curia (formerly AMRI): Curia is a large global CDMO offering sterile injectable development and manufacturing, including aseptic fill-finish and complex formulation services. Its injectable CDMO business overlaps with Oakwood's on commercial and clinical GMP manufacturing of sterile injectable products.
Direct peers
- Carbogen Amcis: Carbogen Amcis is a specialty CDMO with capabilities in highly potent APIs and complex injectable formulations, including aseptic fill-finish and lyophilization services. It competes with Oakwood for complex injectable development and GMP manufacturing projects across multiple therapeutic areas.
- Hovione: Hovione is a contract development and manufacturing organization with explicit expertise in long-acting injectables, including particle engineering and aseptic manufacturing of complex injectables. Its service portfolio (particle-based injectable formulation through commercial supply) overlaps with Oakwood's end-to-end LAI offering.
- Ascendia Pharmaceuticals: Ascendia is a specialty CDMO focused on complex injectable formulations, including emulsions, nanosuspensions and other long-acting injectable formats, with cGMP manufacturing capability. Its service scope (preformulation through commercial manufacturing for difficult-to-formulate molecules) directly overlaps Oakwood's niche in challenging injectable drug delivery.
- Evonik: Evonik operates a Health Care business that is one of the largest CDMOs for polymer-based injectable drug delivery, including PLA/PLGA microspheres used in long-acting injectables. It competes most directly with Oakwood on biodegradable-polymer microsphere formulation and GMP manufacturing services for pharmaceutical clients.
- Lubrizol Life Science: Lubrizol Life Science offers CDMO services in polymeric drug delivery, including PLA/PLGA-based injectable formulations and aseptic manufacturing for complex injectables. The business competes directly with Oakwood for sustained-release injectable formulation development and contract manufacturing engagements.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Oakwood Labs social profiles
Digital presenceOakwood Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oakwood Labs leadership team
Management profileNumber of profiles
Profiles8 records
Oakwood Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oakwood Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oakwood Labs
What does Oakwood Labs do?
Oakwood Labs is a contract development and manufacturing organization (CDMO/CMO) specializing in sustained-release injectable pharmaceuticals based on its patented Chroniject™ polymer microsphere technology. The company provides end-to-end services including feasibility assessments, formulation development, analytical method development, scale-up, and FDA-approved aseptic GMP manufacturing of long-acting injectables for clinical and commercial supply. Oakwood currently manufactures five FDA-approved commercial products for external partners, with three additional registrations pending approval.
Is Oakwood Labs a public or private company?
Oakwood Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Oakwood Labs founded?
Oakwood Labs was founded in 1997. It employs 51 to 100 people.
Where is Oakwood Labs based?
Oakwood Labs is headquartered in Oakwood, United States, in the North America region.
How does Oakwood Labs make money?
Three revenue lines are on record. CDMO Services are the primary driver. The others are contract Manufacturing (CMO) and licensing and Co-development Partnerships.
Who are Oakwood Labs's main competitors?
Broad incumbents on record are Recipharm, Aenova, Vetter Pharma, Baxter BioPharma Solutions and Curia (formerly AMRI). Direct peers are Carbogen Amcis, Hovione, Ascendia Pharmaceuticals, Evonik and Lubrizol Life Science.
Does Oakwood Labs have an API?
No public API is recorded for Oakwood Labs.
What industry is Oakwood Labs in?
Oakwood Labs's product category is Contract Pharmaceutical Manufacturing (CDMO/CMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its SIC code is 8731.